Introduction:
Multiple myeloma (MM) cells accumulate in the bone marrow
and produce enormous quantities of immunoglobulins, causing endoplasmatic reticulum
stress and activation of protein handling machinery, such as heat shock protein
response, autophagy and unfolded protein response (UPR).
Methods:
We evaluated cell lines viability after treatment with bortezomib (B) in
combination with HSP70 (VER-15508) and autophagy (SBI-0206965) or UPR (STF-
083010) inhibitors.
Results:
For RPMI-8226, after 72 hours of treatment with B+VER+STF or B+VER+SBI,
we observed 15% of viable cells, but treatment with B alone was better (90% of cell
death). For U266, treatment with B+VER+STF or with B+VER+SBI for 72 hours resulted
in 20% of cell viability and both treatments were better than treatment with B alone (40%
of cell death). After both triplet combinations, RPMI-8226 and U266 presented the
overexpression of XBP-1 UPR protein, suggesting that it is acting as a compensatory
mechanism, in an attempt of the cell to handle the otherwise lethal large amount of
immunoglobulin overload.
Conclusion:
Our in vitro results provide additional evidence that combinations of protein
homeostasis inhibitors might be explored as treatment options for MM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.